รายงานวิจัยฉบับสมบูรณ์

การวิเคราะห์โปรติโอมิกส์ของ WT1 ที่ถูกยับยั้งด้วย siRNA ในเซลล์มะเร็งเต้านมเพาะเลี้ยงชนิด MCF-7 และ MDA-MB-468

(Proteomics analysis of siRNA-mediated WT1 knockdown in breast cancer cell lines MCF-7 and MDA-MB-468)

คณะนักวิจัย
ดร. กัญญนัช กนกวิรุฬห์
ผศ.ดร. พจนพร ไกรดิษฐ์

โครงการนี้ได้รับทุนสนับสนุนจาก เงินรายได้มหาวิทยาลัย
มหาวิทยาลัยสงขลานครินทร์
ประจำปีงบประมาณ 2555 รหัสโครงการ MED550120S

1. ชื่อโครงการวิจัย

(ภาษาไทย) การวิเคราะห์โปรติโอมิกส์ของ WT1 ที่ถูกยับยั้งด้วย siRNA ในเซลล์มะเร็งเต้านมเพาะเลี้ยงชนิด MCF-7 และ MDA-MB-468

(ภาษาอังกฤษ) Proteomics analysis of siRNA-mediated WT1 knockdown in breast cancer cell lines MCF-7 and MDA-MB-468

2. ผู้รับผิดชอบ

หัวหน้าโครงการ ดร. กัญญนัช กนกวิรุฬห์

ผู้ร่วมโครงการ ผศ.ดร. พจนพร ไกรดิษฐ์

ภาควิชาชีวเวชศาสตร์ คณะแพทยศาสตร์

มหาวิทยาลัยสงขลานครินทร์ วิทยาเขตหาดใหญ่

3. กิตติกรรมประกาศ

This work was financially supported by Prince of Songkla University Research Fund contract number MED550120S. I also thanks to Dr. Sittiruk Roytrakul and staffs at Proteomics Research Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency for their assistance and support in proteomics analysis.

4. บทคัดย่อภาษาไทยและภาษาอังกฤษ

ยีน *WT1* มีส่วนของ zinc finger ทำหน้าที่กระตุ้นหรือยับยั้งยีนหลายชนิดที่เกี่ยวข้องกับการพัฒนา การเจริญเติบโต และการตายแบบอะพอพโตซิสของเซลล์ หน้าที่ที่แตกต่างกันขึ้นอยู่กับชนิดของเซลล์ที่แสดงออก ไอโซฟอร์มของ WT1 และโมเลกุลที่เกี่ยวข้อง การศึกษาครั้งนี้มีวัตถุประสงค์เพื่อศึกษาความสัมพันธ์ระหว่าง WT1 และโปรตีนต่างๆ ในเซลล์มะเร็งเต้านมเพาะเลี้ยงชนิด MCF-7 และ MDA-MB-468 โดยยับยั้งการแสดงออกของ WT1 ด้วย siRNA และใช้โปรติโอมิกส์ในการวิเคราะห์รูปแบบการแสดงออกของโปรตีนด้วยเทคนิคการแยกโปรตีนแบบสองมิติ (2-DE) และการแยกโปรตีนแบบหนึ่งมิติ (1-DE) พร้อมระบุชนิดของโปรตีนด้วยเครื่องแมสสเปกโตรเมทรีชนิด LC-MS/MS ผลการศึกษาด้วยเทคนิค 2D LC MS/MS พบโปรตีน ที่มีการแสดงออกแตกต่างกันระหว่างสภาวะที่มี WT1 เปรียบเทียบกับสภาวะที่ไม่มี WT1 ทั้งหมด 27 ชนิด และ 70 ชนิดในเซลล์ MCF-7 และ MDA-MB-468 ตามลำดับ ในขณะที่ผลการศึกษาด้วยเทคนิค 1D LC-MS/MS พบโปรตีนที่มีการแสดงออกที่แตกต่างกันระหว่างสภาวะที่มี WT1 เปรียบเทียบกับสภาวะที่ไม่มี WT1 ทั้งหมด 164 ชนิดในเซลล์ MCF-7 และ MDA-MB-468 โปรตีนเหล่านั้นทำหน้าที่เกี่ยวข้องกับการตายของเซลล์แบบอะพอพโทสิส การส่งสัญญาณภายในเซลล์ การขดตัวของโปรตีน กระบวนการเมตาบอลิสึม โปรตีนโครงสร้าง การ

เกาะติดของเซลล์ การแสดงออกของยีน การขนส่ง การสลายโปรตีน กระบวน redox ภายในเซลล์ และโปรตีนที่ยังไม่ทราบหน้าที่แน่ชัด จากการวิเคราะห์พบโปรตีนที่เกี่ยวข้องกับการตายของเซลล์แบบอะพอพโทสิส แสดงออกเฉพาะในสภาวะที่ไม่มี WT1 ในเซลล์ MCF-7 ได้แก่ Cathepsin D, apoptosis inducing factor และ apoptosis stimulating of p53 protein เท่านั้น และพบโปรตีนที่เกี่ยวข้องกับกระบวนการส่งสัญญาณภายในเซลล์ ในสภาวะที่มี WT1 ในเซลล์ MCF-7 ชนิด 14-3-3 epsilon, signal transducing adaptor protein 1, phospholipase C และ metabotropic glutamate receptor ส่วนในเซลล์ MDA-MB-468 พบโปรตีนที่น่าสนใจ ได้แก่ ALG-2 interacting protein x, apoptosis- inducing factor 1 guanine nucleotide binding protein, neuropolypeptide h3, platelet derived growth factor receptor (PDGFRA) และ Rho guanine nucleotide exchange factor 1 แสดงออกเฉพาะในสภาวะที่มี WT1 ในขณะที่ IBTK protein, SH2 domain containing protein และ mitogaliain จะแสดงออกเฉพาะในสภาวะที่ไม่มี WT1 เท่านั้น จากการศึกษาครั้งนี้สามารถสรุปได้ว่าเซลล์ MCF-7 WT1 น่าจะมีความสัมพันธ์กับโปรตีนที่เกี่ยวข้องกับอะพอพโทสิสชนิด Cathepsin D, apoptosis-inducing factor 1 และ apoptosis stimulating factor of p53 protein 2 นอกจากนี้ WT1 น่าจะมีความเกี่ยวข้องกับโปรตีนในกระบวนการส่งสัญญาณภายในเซลล์ชนิด 14-3-3 epsilon, signal transducing adaptor protein 1, phospholipase C, and metabotropic glutamate receptor ส่งผลให้ WT1 นั้นน่าจะมีบทบาทเป็น oncogene และโปรตีนต้านการตายของเซลล์แบบอะพอพโทสิส ส่วนในเซลล์ MDA-MB-468 นั้นคาดว่า WT1 น่าจะมีความสัมพันธ์กับโปรตีนที่เกี่ยวข้องกับอะพอพโทสิสชนิด mitogaligin และโปรตีนที่เกี่ยวข้องกับการส่งสัญญาณภายในเซลล์ชนิด platelet derived growth factor receptor alpha และ rho guanine nucleotide exchange factor 1 ส่งสัญญาณผ่านทาง mTOR รวมทั้งอาจจะควบคุมการทำงาน Raf kinase inhibitor protein ซึ่งส่งผลให้การส่งสัญญาณผ่านทาง Raf/MAP kinase pathway เกิดได้และส่งเสริมกระบวนการ metastasis อย่างไรก็ตาม ควรทำการยืนยันผลการทดลองเพิ่มเติมเพื่อยืนยันสมมติฐานดังกล่าว

The Wilms' tumor 1 (*WT1*) gene encodes a zinc finger acting as a transcriptional activator or repressor for many genes involved in cell differentiation, growth, and apoptosis. These functions depend on the cell types, WT1 isoforms, and the status of targeted molecules. To determine the relationship between WT1 and related proteins, WT1 was silenced with siRNA in MCF-7 and MDA-MB-468 breast cancer cell lines. The protein expression patterns were analyzed by proteomics techniques: two-dimensional gel electrophoresis (2-DE) and one-dimensional gel electrophoresis (1-DE) combined with LC-MS/MS mass spectrometry. For 2-DE LC-MS/MS analysis, 27 protein spots (15 spots in $siRNA_{neg}$ (present WT1) and 12 spots in $siRNA_{WT1}$ (without WT1)) were found to

have a significant change in expression level. However, in MDA-MB-468, 70 protein spots (61 spots in $siRNA_{neg}$ (present WT1) and 9 spots in $siRNA_{WT1}$ (without WT1)) had a significant change in expression level. While, 1-DE LC-MS/MS showed 164 proteins differentially expressed between $siRNA_{neg}$ and $siRNA_{WT1}$ in MCF-7 and MDA-MB-468. These proteins could be classified by their functions in apoptosis, cell signaling, protein folding, metabolism, structural, cell adhesion, gene expression, transport, redox-regulation, protein degradation and unknown functions. In MCF-7, the proteins involving apoptosis were cathepsin D, apoptosis inducing factor, and apoptosis stimulating of p53 protein and were found only in silenced WT1 condition. In the presence of WT1, the following proteins involving signal transduction pathway were found: 14-3-3 epsilon, signal transducing adaptor protein 1, phospholipase C, and metabotropic glutamate 5 receptor. In MDA-MB-468, proteins involving apoptosis including ALG-2 interacting protein x and apoptosis- inducing factor 1 were up-regulated in the presence of WT1, while mitogaligin, an apoptosis related molecule, was identified when WT1 was silenced. On the other hand, proteins related in the signaling pathway were detected in both $siRNA_{neg}$ and $siRNA_{WT1}$ but the type of proteins were different. For example, IBTK protein, and SH2 domain containing protein were present in $siRNA_{WT1}$ condition, while the platelet derived growth factor receptor (PDGFRA**),** rho guanine nucleotide exchange factor 1, guanine nucleotide binding protein, and neuropolypeptide h3 were expressed in $siRNA_{neg}$. From these results it may be assumed that WT1 could be related with proteins involved in apoptosis: cathepsin D, apoptosis-inducing factor 1, and apoptosis stimulating factor of p53 protein 2 and may play a role as an anti-apoptosis in MCF-7. While in the signal transduction pathway, WT1 may crosstalk with 14-3-3 epsilon, signal transducing adaptor protein 1, phospholipase C, and metabotropic glutamate receptor resulting in cell growth or cell proliferation. Thus, WT1 acts as an oncogene in MCF-7. In MDA-MB-468, WT1 relates to mitogaligin and behaves as an anti-apoptotic molecule. Moreover, WT1 may be associated with the platelet derived growth factor receptor alpha, rho guanine nucleotide exchange factor 1 that activates proliferation via the mTOR

pathway. Furthermore, WT1 may act as a negative regulator or block Raf kinase inhibitor resulting in activation of the MAPK pathway and promote metastasis. However, validation of the selected protein is necessary to confirm these hypotheses.

5. Executive Summary

Introduction

Breast cancer is the most common cancer and the leading cause of death in women worldwide accounting for 23% (1.38 million cases) of the total new cancer cases and 14% (458,400 cases) of the total cancer deaths in 2008 (Jemal *et al*., 2011). In Thailand, breast cancer is the most common diagnosed cancer in Thai women, of which the ASR is 20.9 per 100,000 in women and 0.3 per 100,000 in men (Khuhaprema *et al.*, 2010). Breast cancer might result from an interaction between the change in genetic elements, environmental factors, and also the difference in ethnicity (Adami *et al*., 1998). Genes involved in breast cancer are *BRCA1* (Breast cancer gene 1) and *BRCA2* (Breast cancer gene 2). These genes are related to hereditary breast cancer (5-9% of breast cancer). Moreover, there are many genes associated with breast cancer, such as *ERBB2, c-Myc, CCND1, TP53, PTEN*, and *WT1* (Dumitrescu and Cotarla, 2005).

The human Wilms' tumor 1 (*WT1*) gene is located at chromosome locus 11p13. This gene encodes 10 exons. Alternative splicing occurs at exon 5 (plus or minus 17AA) and exon 9 (plus or minus KTS) in mRNA of WT1. These two alternative splicing sites yield four different isoforms: WT1 +/+, WT1+/-, WT1-/+, and WT1-/- (Gessler *et al.*, 1990; Haber *et al*., 1993). WT1 encodes a zinc finger acting as a transcriptional activator or repressor for many genes. These genes are involved in cell differentiation, growth, and apoptosis. WT1 functions depend on the type of cells, WT1 isoforms and the status of targeted molecules. There are several targeted molecules for WT1 including growth factor genes: IGF-II, PDGF-A, CSF-1, TGF-β1, growth factor receptor genes: insulin receptor, IGF-1R and EGFR, and transcription factor and other genes: Egr1, PAX4, p53, c-myc, Bcl-2, cyclin E, Bak, Bax, etc. (Yang *et al.* 2007; Graidist *et al.*, 2009). However, the

overview study of the relationship between WT1 and the related molecules in breast cancer has not been reported.

In this study, we used siRNA against WT1 mRNA to silence WT1 expression and the relationship between WT1 and related proteins in breast cancer cell lines MCF-7 and MDA-MB-468 was investigated by proteomics analysis. The proteins were further identified by LC-MS/MS and database searching. These studies may provide more evidences to understand the relationship of WT1 and the related molecules in breast cancer.

Objective

To determine the relationship between WT1 and related proteins, WT1 was silenced with siRNA in MCF-7 and MDA-MB-468 breast cancer cell lines

Conclusions

One dimensional gel electrophoresis (1D-PAGE)

The quantitative proteomic, one-dimensional gel electrophoresis (1D-PAGE) was also carried out to determine the protein expression patterns between $siRNA_{neg}$ compared to $siRNA_{WT1}$ in MCF-7 and MDA-MB-468. Figure 1 represents the protein patterns obtained from 1D-PAGE. Lane 1 and 2 shows the protein bands of $siRNA_{neg}$ and $siRNA_{WT1}$ in MCF-7. While lane 3 and 4 shows the protein bands of $siRNA_{neg}$ and $siRNA_{WT1}$ in MDA-MB-468. After 1D-PAGE, the gels were cut into 15 slices as shown in Figure 1B.



M = Marker

1= MCF-7 control cell ($siRNA_{neg}$)

2 = MCF-7 transfected with $siRNA_{WT1}$

3 = MDA-MB-468 control cell ($siRNA_{neg}$)

4 = MDA-MB-468 transfected with $siRNA_{WT1}$

Figure 1 12.5% SDS-gel image of protein pattern between $siRNA_{neg}$ compared to $siRNA_{WT1}$ in MCF-7 and MDA-MB-468 (A) and gel after fractionation into 15 slices (B)

1 Identification of differential protein expression by 1-DE and LC-MS/MS

The quantification of protein from 1D-PAGE was analyzed by the DeCyder™ MS 2.0 Differential Analysis Software (GE Healthcare). The protein expressions of all four conditions were compared together including MCF-7 $siRNA_{WT1}$ (MS), MCF-7 $siRNA_{neg}$ (MN), MDA-MB-468 $siRNA_{WT1}$ (DS), and MDA-MB-468 $siRNA_{neg}$ (DN). The protein expressions with different intensity among these four conditions were shown in Venn's diagram which demonstrated all possible relations of protein expressions in all four conditions (Figure 2). There were 12, 11, 12, and 14 proteins expressed only in MS, MN, DS, and DN, respectively. Furthermore, there were 23 proteins expressed in both MS and MN, 14 proteins expressed in DS and DN, 9 proteins expressed in MS and DS, 11 proteins expressed in MS and DN, 4 proteins expressed in MN and DS, and 5 proteins expressed in MN and DN. Moreover there were 13 proteins

expressed along in MS, MN, and DN, 13 proteins expressed in MN, DN, and DS, 15 proteins expressed in MS, DN, and DS as well as 11 proteins expressed in MS, MN, and DS. However, there were 219 proteins expressed together in MN, MS, DN, and DS. The protein names and their biological functions have been listed in Table 1-15.



Figure 2 Venn's diagram of protein expression with different intensity between siRNA$_{WT1}$ transfection and siRNA$_{neg}$ control of MCF-7 and MDA-MB-468 (MN= MCF-7 siRNA$_{neg,}$ MS = MCF-7 siRNA$_{WT1}$, DS = MDA-MB-468 siRNA$_{WT1}$, and DN = MDA-MB-468 siRNA$_{neg}$)



Figure 3 Functions of differentially expressed proteins between $siRNA_{WT1}$ and $siRNA_{neg}$ in MDA-MB-468 and MCF-7









Figure 3 (Continued)









Figure 3 (Continued)





Figure 3 (Continued)



Figure 3 (Continued)

Table 1 Identification of expressed proteins only found in MDA-MB-468 $siRNA_{WT1}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Apoptosis			
mitogaligin	gi|12005991	AWRMGEPACWGR	9.50
Cell signaling			
IBTK protein, partial	gi|34192875	SLDVLSDGVLK	27.56
SH2 domain-containing protein 3C isoform a	gi|41281821	RSSASISR	11.47
Structural protein			
cytokeratin 9	gi|435476	GGSGGSYGGGGSGGGYGGGSGSR	91.06
Keratin 10	gi|21961605	SQYEQLAEQNRK	50.17
keratin, type II cytoskeletal 1	gi|119395750	SLNNQFASFIDK	98.71
type I keratin 16	gi|1195531	APSTYGGGLSVSSR	30.64
Protein folding			
Ankyrin repeat domain-containing protein 62	gi|302393830	LNDLNDRDK	13.03
Gene regulation			
SON DNA binding protein isoform E	gi|17046381	NRDKGEKEK	10.73
Redox-regulation			
selenoprotein I	gi|119621096	KMAASTRVEASR	5.30
Transport			
synaptosomal-associated protein 23 isoform SNAP23A	gi|18765729	KLIDS	4.17

Table 1 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Unknown			
hCG2042301	gi|119611404	TGGDRTKAQRHEIISLS	11.14
unknown protein IT12	gi|2792366	SGARAMAKAKK	7.15
unnamed protein product	gi|21757251	LINDSTNK	19.40

Table 2 Identification of expressed proteins only found in MDA-MB-468 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Cell adhesion			
vang-like protein 1 isoform 1	gi|20373171	HMAGLK	12.95
Cell differentiation			
METRNL protein, partial	gi|30047763	VFEPVPEGDGHWQGR	10.04
Cell signaling			
PDGFRA protein	gi|39645305	VPSIKLVYTLTVPEATVK	11.73
rho guanine nucleotide exchange factor 11 isoform 1	gi|7662086	SSNSK	6.04

Table 2 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Structural			
Keratin 5	gi|18999435	LAELEEALQK	23.61
peroxisome assembly protein 26 isoform a	gi|8923625	KSDSSTSAAPLR	6.59
hHa7 protein	gi|50949256	NTLNGHEK	12.35
Transport			
Na+/K+ -ATPase alpha 3 subunit variant	gi|62898870	LNIPVSQVNPR	14.46
Unknown function			
unnamed protein product	gi|194390014	MFHLAAFKLK	22.44
hCG2042050	gi|119579649	ASTVPDLK	7.42
chromosome 9 open reading frame 39	gi|119579068	LLEGQSLALSPR	11.96
hypothetical protein LOC286076	gi|119602615	DVGDALPR	29.47

Table 3 Identification of expressed proteins only found in MCF-7 $siRNA_{WT1}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Apoptosis			
Apoptosis-stimulating of p53 protein 2	gi|33860140	ENGVNSPR	37.14
apoptosis-inducing factor 1, mitochondrial isoform 5 precursor	gi|195927006	QMASSGASGGK	9.7

Table 3 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Cell division			
centrosomal protein of 63 kDa isoform b	gi|109255239	KQMREFRGNTK	5.37
Transport			
solute carrier family 12 member 9 isoform 1	gi|31881740	ILHALAR	28.14
Structural proteins			
keratin 19	gi|7594732	AALEDTLAETEAR	80.11
Gene regulation			
GATA zinc finger domain-containing protein 1	gi|88759346	SSPFPTVPTRPEK	19.38
M-phase phosphoprotein, mpp8, isoform CRA_a	gi|119628633	YQKRHDSDK	12.38
cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1	gi|24307983	NFVLDNTDR	7.37
eukaryotic translation initiation factor 4 gamma, 3, isoform CRA_a	gi|297283576	AGKIVVNLTGR	1.87
Unknown function			
SRSQ1913	gi|37181514	AVALDLPGFGNSAPSK	11.91
hCG1781582	gi|119603082	KTRMEDTFWNSRLDNISR	11.78
unnamed protein product	gi|14042413	KKSKPCLIK	14.36

Table 4 Identification of expressed proteins only found in MCF-7 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	**Accession number**	**Peptide**	**Mowse Score**
Cell signaling			
Phospholipase C, delta 1 variant	gi|62089310	GAVATQVSPAVPLPPR	10.01
metabotropic glutamate receptor 5 isoform B precursor	gi|4504143	RLMETPNAR	16.38
Structural protein			
tubulin alpha-1C chain	gi|14389309	DVNAAIATIK	40.29
keratin, type I cytoskeletal 18	gi|4557888	AQIFANTVDNAR	57.19
Fatty acid biosynthesis			
fatty acid synthase	gi|119610151	LQVVDQPLPVR	41.03
Redox-regulation			
Cu/Zn-superoxide dismutase	gi|1237406	KHGGPK	4.35
Transport			
anion exchange transporter isoform a	gi|16306483	KFYTDLMNMIQK	13.97
Unknown function			
hCG1739111, isoform CRA_a	gi|119613684	MMSGPVPQCLR	1.26
Hypothetical protein DKFZp434O1826 variant	gi|62089384	QGTEERQPRSR	3.11

Table 4 (Continued)

Protein name	Accession number	Peptide	Mowse Score
unnamed protein product	gi|193788364	MEGKKPRVMAGTLK	10.55
Chromosome 9 open reading frame 139	gi|124376896	LAGSLATDLSR	15.44

Table 5 Identification of expressed proteins found in MDA-MB-468 $siRNA_{WT1}$ and MDA-MB-468 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Structural protein			
LMNA protein	gi|21619981	SGAQASSTPLSPTR	44.82
Cell differentiation and survival			
Nance-Horan syndrome protein isoform 2	gi|42384238	KTISGIPR	26.98
sestrin-2	gi|13899299	KLSEINK	21.68
Cell signaling			
S100 calcium binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)), isoform CRA_b	gi|119573783	NALSGAGEASAR	11.49
Chain A, Catalytic Domain Of Human Phosphodiesterase 4b In Complex With Piclamilast	gi|58177395	GMEISPMXDK	8.66
protein S100-A6	gi|7657532	LQDAEIAR	43.91

Table 5 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Hormone			
C-type natriuretic peptide precursor	gi|13249346	YKGANKKGLSK	10.08
Protein folding			
heat shock protein	gi|4204880	IINEPTAAAIAYGLDKK	27.1
Transport			
ras association domain-containing protein 9	gi|114155158	ADAFLPVPLWR	6.35
Gene regulation			
TTLL5 protein	gi|33877151	MGNTMDKR	10.31
39S ribosomal protein L15, mitochondrial	gi|7661806	CGRGHK	16.37
Unknown function			
hCG16415, isoform CRA_f	gi|119611935	GAECCPGGPVK	10.83
FLJ00258 protein	gi|18676718	GSMSR	8.83
pyruvate dehydrogenase E1 alpha subunit	gi|861534	EEIPPHSYR	6.28

Table 6 Identification of expressed proteins found in MCF-7 $siRNA_{WT1}$ and MCF-7 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Cell signaling			
orphan G protein-coupled receptor HG20	gi|4836218	FQGSEPPK	21.41
MAPKBP1 protein	gi|71297458	WACLGEGTTPKPR	12.72
calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B isoform 1	gi|4505677	SDAVPSEVR	17
Structural protein			
Chain A, Crystal Structure Of Human Full-Length Vinculin	gi|83753119	KLEAXTNSKQSIAK	9.63
Immune system			
PREDICTED: HLA class II histocompatibility antigen, DRB1-7 beta chain-like isoform 3	gi|310124860	LRKSPGMLEK	11.26
Gene regulation			
non-histone chromosomal protein HMG-14	gi|48255933	RKVSSAEGAAK	5.73
serine/threonine-protein kinase SMG1	gi|62243658	LSSGGGGGGTKYPR	6.52
zinc finger protein 38, isoform CRA_b	gi|119597017	ASVSMRASAPTR	6.45
ORF	gi|434765	AAGIR	4.95
U2AF1-RS1	gi|1125020	IKKEKEEAAK	11.82

Table 6 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Transport			
Golgin subfamily A member 7B	gi|58219040	GLLLTDPVERGMR	16.12
stomatin-like protein 3 isoform 2	gi|221316744	VLAAEGEMNASK	14.3
Apoptosis			
NACHT, LRR and PYD domains-containing protein 7 isoform 2	gi|75709196	MGPCSFAELISK	7.37
Cell cycle			
NIMA-related kinase 6	gi|10121890	MLHRSPSGTRARPR	8.17
Unknown function			
FLJ00020 protein	gi|10440371	QGRPLPR	18.8
hCG1783738, isoform CRA_b	gi|119606482	KRHEASMFR	2.96
SLC44A1 protein, partial	gi|17390479	EAGKGGVADSR	13.48
unnamed protein product	gi|10433066	QGAKEKQLLK	39.4
protein FAM181B	gi|54873602	LALDKPGKSK	11.59
unnamed protein product	gi|194378218	DASQVSAPGTRR	8.81
similar to RIKEN cDNA 1700011J18	gi|119607333	LILVSKSLEFLDGK	14.65
KIAA0411 protein	gi|25535933	LSXISEDVIR	17.36
hypothetical protein LOC286076	gi|119602615	DVGDALPR	21.23

Table 7 Identification of expressed proteins found in MCF-7 $siRNA_{WT1}$ and MDA-MB-468 $siRNA_{WT1}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Cell signaling			
2-5A-dependent ribonuclease	gi|10863929	GGATALMDAAEK	10.33
centaurin beta2	gi|4688902	EAYIRAKYVER	4.90
PDE4D protein	gi|14249999	LSPVISPR	28.91
Stress response			
SGK-like protein SGKL	gi|17402861	KKRFTVYK	8.89
Gene regulation			
DNA-directed RNA polymerases I and III subunit RPAC2 isoform 1	gi|7705740	TSMAEGERK	14.28
Transport			
stathmin-like 3, isoform CRA_b	gi|119595656	AAAPSAAR	11.10
Unknown function			
KIAA0338	gi|2224617	GTPEKANERAGLR	6.93
unnamed protein product	gi|21751864	IKKANECASR	11.11
CYorf15A protein	gi|83405816	QGLSLSPR	29.27

Table 8 Identification of expressed proteins found in MCF-7 $siRNA_{WT1}$ and MDA-MB-468 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Cell proliferation			
Calcium homeostasis endoplasmic reticulum protein	gi|18204653	NSGPSRSRSR	14.73
Cell signaling			
Mitogen-Activated Protein Kinase Kinase Kinase 3	gi|83754682	SSSXK	9.13
Cell adhesion			
Neural cell adhesion molecule 1	gi|28703938	SHARVSSLTLK	4.4
Structural protein			
Keratin 8	gi|49256423	ISSSSFSR	55.86
sperm-associated antigen 17	gi|46240864	TRKEIETTQNYLMDIKNR	15.76
myosin regulatory light chain 10	gi|34147532	ESLALSPR	29.6
Protein folding			
90kDa heat shock protein	gi|306891	ADLINNLGTIAK	64.95
Unknown function			
hCG1813960	gi|119615973	MESLQCASGTLK	5.59
KIAA0483 protein	gi|3413926	IVPILKR	8.96

Table 8 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Unknown function			
KIAA1712 protein	gi|12697969	VMATGDLKRSLR	9.33
unnamed protein product	gi|16551723	MHNAAR	15.37

Table 9 Identification of expressed proteins found in MDA-MB-468 $siRNA_{WT1}$ and MCF-7 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Gene regulation			
RNA-binding protein 5	gi|5032031	MGSDK	1.11
Immune system			
MHC class II regulatory factor RFX1	gi|238859557	FEPVLQWTK	5.57
Unknown function			
unnamed protein product	gi|21755689	QDILDEMRK	14.97
N-acetylserotonin O-methyltransferase-like protein isoform 1	gi|117553627	MVLCPVIGK	8.56

Table 10 Identification of expressed proteins found in MDA-MB-468 $siRNA_{neg}$ and MCF-7 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Structural protein			
talin-1	gi|223029410	MATNAAAQNAIKKK	4.8
Transport			
mitochondrial dicarboxylate carrier isoform	gi|20149598	LFSGATMASSR	7.2
Unknown function			
hypothetical protein	gi|8246847	MGPTK	1.97
KIAA1311 protein	gi|7242977	QEVLEKQIECQK	14.75
unnamed protein product	gi|194375249	AEAGT	9.34

Table 11 Identification of expressed proteins found in MCF-7 $siRNA_{WT1}$, MCF-7 $siRNA_{neg}$, and MDA-MB-468 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Calcium binding protein			
calretinin	gi|825634	GSGMMSK	18.67

Table 11 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Structural protein			
keratin type II	gi|914833	NKYEDEINKR	26.10
myosin-IIIa	gi|145275208	KEIVDMK	10.30
Oesteogenesis			
leucine-rich repeat-containing protein 17 isoform 2 precursor	gi|239582714	KASPGSVRSR	18.37
Gene regulation			
enhancer of mRNA-decapping protein 4	gi|45827771	VPAPR	5.32
heterogeneous nuclear ribonucleoproteins C1/C2 isoform	gi|117190174	VPPPPPIAR	9.87
chorion-specific transcription factor GCMb	gi|4758420	SETEAR	23.01
Transmembrane protein			
leucine-rich repeat neuronal 6A	gi|37675422	HLVSAK	8.59
Tumor suppressor			
adenomatous polyposis coli homolog APC2	gi|6018189	EDYRQVLR	9.70
Unknown function			
unnamed protein product	gi|194386918	ALLVG	5.56
unnamed protein product	gi|194376292	FGSIPK	5.59

Table 12 Identification of expressed proteins found in MCF-7 $siRNA_{neg}$, MDA-MB-468 $siRNA_{WT1}$, and MDA-MB-468 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Apoptosis			
lymphotoxin alpha transcript variant 6	gi|78370182	SPELSKKEF	4.96
inactive caspase-12	gi|300360580	AGADTHGRLLQGNICNDAVTK	20.82
Cell proliferation			
oncoprotein-induced transcript 3 protein precursor	gi|22749297	NSPLEIMSR	21.97
Immune system			
Ig heavy chain DJ region (clone C100-94) - human (fragment)	gi|345998	AMVXLLGPGT	31.6
Protein folding			
heat shock 60kDa protein 1 (chaperonin), isoform CRA_c	gi|119590557	VTDALNATR	37.44
heat shock protein 105 kDa	gi|42544159	ANEKK	3.89
Receptor			
sphingosine 1-phosphate receptor 3	gi|38788193	MATALPPR	24.17
Gene regulation			
LIM homeobox transcription factor 1-alpha	gi|28893581	GTAEEGKDHK	9.47
Zinc finger protein 181	gi|71297022	HQRIHTMEK	7.25
signal recognition particle 19 kDa protein isoform 1	gi|4507213	TIAEGR	2.27

Table 12 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Unknown function			
hCG1649526, isoform CRA_a	gi|119583049	RSPAAGIR	15.13

Table 13 Identification of expressed proteins found in MCF-7 $siRNA_{WT1}$, MDA-MB-468 $siRNA_{WT1}$, and MDA-MB-468 $siRNA_{neg}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Gene regulation			
adenosine deaminase domain-containing protein 2 isoform 2	gi|223972690	QLLLATQGGPK	7.01
eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa, isoform CRA_f	gi|119620997	TPGKANAK	10.22
coiled-coil and C2 domain-containing protein 2A isoform	gi|257900481	QNKNSKVR	10.76
Metabolism			
glyceraldehyde-3-phosphate dehydrogenase	gi|31645	IISNASCTTNCLAPLAK	78.7
Nucleotide biosysthesis			
phosphoribosyl pyrophosphate synthase-associated protein 2 isoform 1	gi|4506133	NAVIVAK	15.58
Protein-protein interaction			
tetratricopeptide repeat protein 22 isoform 1	gi|166235180	AKMGLGGMPDR	10.29

Table 13 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Transport			
ATP synthase subunit alpha, mitochondrial isoform c	gi|50345982	VLSIGDGIAR	16.53
Tpr	gi|633226	AIVAAK	1.15
vacuolar proton ATPase	gi|313014	AEEEFNIEK	11.8
N-methyl D-aspartate subunit 3A]	gi|20372905	AEALWPR	20.96
Unknown function			
unnamed protein product	gi|10438636	KSRPLTNSVKL	11.17
unnamed protein product	gi|7021931	NRDNQSMLIT	12.75
hCG2040455	gi|119601467	QEEDCRKVSR	8.46
unnamed protein product	gi|194378218	DASQVSAPGTRR	8.81
ALS2CR11	gi|15823651	GNSSLIKEQK	4.2

Table 14 Identification of expressed proteins found in MCF-7 $siRNA_{WT1}$, MCF-7 $siRNA_{neg}$, and MDA-MB-468 7 $siRNA_{WT1}$ using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Cell proliferation			
Angiopoietin-like 5	gi|29351676	LLATGIQWGTWTK	8.06
Immune system			
immunoglobulin heavy chain variable region	gi|145939619	ATTGA	6.98
Protein folding			
heat shock protein beta-1	gi|4504517	QLSSGVSEIR	41.36
Gene regulation			
zinc finger MYM-type protein 3 isoform 1	gi|4827067	SPRMSLR	22.91
Transport			
mucolipin-3 isoform 1	gi|24496763	KLKFFFMNPCEK	9.89
vesicular acetylcholine transporter	gi|507744	NVGLLTR	17.9
Unknown function			
hCG1749575, isoform CRA_a	gi|119625824	DGRGIIIFPR	15.28
unnamed protein product	gi|194381006	AARAWEGDAR	7.73
hypothetical protein	gi|52545574	ITDYALIAIGR	12.5

Table 14 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Unknown function			
hCG2014677, isoform CRA_d	gi|119617550	ATSKAPQGSNSK	7.84
unnamed protein product	gi|34527456	MDLKCKKMK	13.1

Table 15 Identification of expressed proteins found in MCF-7 $siRNA_{neg}$, MCF-7 $siRNA_{WT1}$, MDA-MB-468 $siRNA_{WT1}$, and MDA-MB-468 $siRNA_{WT1}$using DeCyder™ MS 2.0 Differential Analysis Software

Protein name	Accession number	Peptide	Mowse Score
Apoptosis			
caspase recruitment domain protein 10	gi|13488607	EEDPAPPK	40.78
dead end protein homolog 1	gi|34740339	AAAMAK	7.54
niban-like protein 2 isoform b	gi|148664236	KEVPLSR	13.88
protocadherin gamma-A4 isoform 2 precursor	gi|14196468	VAENENPGAR	4.54
Cell adhesion			
trophinin, isoform CRA_b	gi|119613608	MHTLLAATK	5.98

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Carbohydrate, lipid, and steroid biosysnthesis			
alpha-1,2-mannosyltransferase ALG9 isoform b	gi|118026933	LKGSGASSGDTAPAADK	21.34
ethanolamine kinase 2	gi|55960794	LGGGTAEGKTGR	15.3
steroid 21-hydroxylase	gi|253757549	LKQAIXKR	13.42
Cell cycle, cell division, cell growth, cell proliferation			
STON1 protein	gi|111309209	IDRLPDK	27.95
thrombopoietin	gi|3986139	QSLLGTQTR	10.79
Titin	gi|17066105	NAVGVSLPR	30.51
cell division cycle 2-like 5 isoform 2 variant	gi|62897667	QMGMTDDVSTIK	8.63
G1 to S phase transition 2	gi|23271293	LPIVDKYK	19.77
separase	gi|38349532	AVRADTGQER	13.31
synaptonemal complex protein 3	gi|24233580	ILNMFR	16.8
placental lactogen	gi|229348	VQTVPLSR	22.76
Chain B, Crystal Structure Of Human Gins Complex	gi|150261226	QVLEEXK	18.55
fibroblast growth factor 6 precursor	gi|15147343	GVVSLFGVRSALFVAMNSKGR	11.06

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Cell signaling			
beige-like protein	gi|21434741	LLASKSEGIR	13.76
dedicator of cytokinesis 4, isoform CRA_d	gi|119603875	GGKTN	5.82
adapter molecule crk isoform b	gi|41327710	GMIPVPYVEK	4.61
A-kinase anchor protein 9 isoform 2	gi|22538387	LEVTKREK	11.98
Chain A, Crystal Structure Of Vegfr2 In Complex With A 3,4,5-Trimethoxy Aniline Containing Pyrimidine	gi|209156455	IXDFGLAR	25.98
inositol 1,4,5-trisphosphate receptor type 1	gi|46107962	ACNNTXDRK	5.56
IQ motif containing GTPase activating protein 3, isoform CRA_	gi|119573332	NLLAMTDK	21.36
MOB kinase activator 3A	gi|18677731	ILSRLFR	28.28
protein kinase, cAMP-dependent, catalytic, gamma	gi|119582876	EFSEF	21.01
protein phosphatase 2A B'alpha1 regulatory subunit	gi| gi|31083236	IMEPLFR	25.71
RADIL protein	gi|33870359	NGPSGLR	16.11
Regulator of G-protein signaling 22	gi|92095662	HLEKMK	12.58
serine/threonine-protein kinase WNK2	gi|32455273	EQQDVGSPDK	12.63
Similar to protein tyrosine phosphatase, non-receptor type 18 (brain-derived), partial	gi|18999432	GAMSR	1.74

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Cell signaling			
SIRP-beta1	gi|2052058	VTTVSELTKR	23.63
V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)	gi|111305899	LENLMR	29.69
Cell-cell interaction			
AIDA-1b	gi|31746739	IMSSIDVGINNELK	18.8
Structural proteins			
nestin, isoform CRA_c	gi|119573310	VQGLEGPR	19.74
tektin 3 variant	gi|62898800	SQRVSENTMLPFVSNR	16.14
tektin-1	gi|16753231	LLQPPPK	20.61
tektin-1	gi|16753231	LLQPPPK	20.61
Abelson tyrosine-protein kinase 2 isoform d	gi|209862772	RNAPTPPK	17.63
beta-actin-like protein 2	gi|63055057	VAPDEHPILLTEAPLNPK	28.69
beta-tubulin	gi|2119276	LAVNMVPFPR	45.12
caldesmon 1, isoform CRA_d	gi|119604235	MRSQKGMIFLTK	10.55
cytokeratin	gi|1419564	LSELEAALQR	77.02
cytokeratin type II	gi|3901030	AQYEDIANR	43.55

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Structural proteins			
cytoplasmic dynein 1 light intermediate chain 2	gi|5453634	QPATPTR	15.32
DNAH1 variant protein	gi|34532301	NPGMR	1.97
integrin, alpha E	gi|119610886	LRGLQVVAVK	12.8
keratin	gi|1200072	QEELEAALQR	21.19
keratin 19	gi|7594734	IVLQIDNAR	63.6
keratin, type I cytoskeletal 17	gi|4557701	TKFETEQALR	23.83
mutant beta-actin (beta'-actin)	gi|28336	AGFAGDDAPR	62.28
myotubularin-related protein 6	gi|134142348	NMYHQFDR	5.65
protein 4.1 isoform 1	gi|260436831	LAPNQTK	9.85
Fibrinolysis			
Plasminogen	gi|38051823	LSSPADITDK	36.06
Immune system			
complement C4-B-like preproprotein	gi|338858017	FGLLDEDGKK	0.4
C-type lectin domain family 3 member A isoform 2	gi|348041279	GGILVIPR	22.39
human complement C1r	gi|179644	NEQKGEKIPR	9.91

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Immune system			
Ig lambda-chain (V-D-J) precursor, partial	gi|186110	SPQYLLRHR	13.06
IL25	gi|18034676	ASEDGPLNSR	27.98
immunoglobulin heavy chain variable region	gi|16075862	KAGSSVRVSCK	10.36
immunoglobulin lambda chain variable region	gi|16075980	RPXGLSPR	17.66
immunoglobulin light chain variable region	gi|109693140	GLTFGGGTK	12.82
T cell receptor beta chain CDR3	gi|3859246	TGGQFFG	12.71
TLR10	gi|67626189	AAVNVNVLATR	4.25
Metabolism			
ADPRHL2	gi|48146591	MAAAAMAAAAGGGAGAARSLSRFR	7.98
aldolase A protein	gi|28595	ELSDIAHR	10.11
DDX27 protein, partial	gi|32425487	ADTLKVKDR	13.32
enolase	gi|31179	IGAEVYHNLK	19.22
enoyl-CoA hydratase	gi|1922287	SLAMEMVLTGDR	10.6
glyceraldehyde-3-phosphate dehydrogenase	gi|31645	GALQNIIPASTGAAK	43.62
L-lactate dehydrogenase A chain isoform 2	gi|207028494	VTLTSEEEAR	27.21

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Metabolism			
lysosomal acid lipase/cholesteryl ester hydrolase precursor	gi|51317399	IINLMR	12.8
short-chain dehydrogenase/reductase family 9C member 7	gi|22507405	LKNIMQVAEPR	14.26
UDP-glucose 6-dehydrogenase isoform 3	gi|296040438	LAANAFLAQR	57.95
Protein folding			
78 kDa glucose-regulated protein precursor	gi|16507237	ITITNDQNR	39.47
chaperonin (HSP60)	gi|306890	GYISPYFINTSK	31.34
HSP70-HOM	gi|4529894	TTPSYVAFTDTER	58.04
mitochondrial heat shock 60kD protein 1 variant 1	gi|189502784	TVIIEQSWGSPK	16.48
prefoldin subunit 4	gi|12408677	AATMK	1.54
proteasome 26S ATPase subunit 1 variant	gi|62896895	AVANQTSATFLR	8.33
proteasome subunit	gi|565651	NISRIMR	24.31
protein unc-45 homolog A isoform 3	gi|89179321	QFAEGSTLK	16.8
TRAP1	gi|3273383	GVVDSEDIPLNLSR	87.94
Tumor marker			
breast cancer resistance marker 1	gi|30231005	IAGTK	13.7

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Proteolysis			
Cocaine esterase	gi|46576349	RLHRLRAR	6.9
DDB1- and CUL4-associated factor 15	gi|78486540	ISGQLSPR	26
DIP2B protein	gi|38014007	YHPIDIETSVSR	10.55
epidermal type II transmembrane serine protease	gi|45861650	TVGFGTRSR	20.42
F-box protein 16, isoform CRA_a	gi|119583916	AQSMMSLSASSPLK	20.73
procollagen galactosyltransferase 1 precursor	gi|31377697	LMNLMR	30.11
Receptor			
dopamine receptor D2longer	gi|7381416	AHLRAPLK	23.71
glutamate receptor, ionotropic, delta 2 variant	gi|62088216	LENNMR	20.78
nicotinic acetylcholine receptor beta-3 subunit	gi|34988	LPKLLCMK	22.62
olfactory receptor 51B6	gi|52353945	TVMGIGSGGER	9.15
oxytocin receptor	gi|32307152	FLCCSASYLK	19.4
Redox-regulation			
cytochrome c oxidase subunit	gi|119622335	KLTERRK	15.99
Chain A, Monomeric Human Cu,Zn Superoxide Dismutase Without Zn Ligands	gi|240104588	SGGPK	10.37
peroxiredoxin-1	gi|4505591	QITVNDLPVGR	41.73

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Stress response			
oxidation resistance 1, isoform CRA_c	gi|119612311	GTANR	7.44
Gene regulation			
cullin-1	gi|32307161	MSSTR	0.49
DNA repair protein RAD50	gi|19924129	INEDMR	21.41
ubiquitin specific peptidase 25, isoform CRA_c	gi|119630448	NLPFMR	28.65
ubiquitin-like modifier-activating enzyme ATG7 isoform a	gi|5453668	TADKK	14.03
cullin-4B isoform 1	gi|121114298	IMIIFR	32.82
thymidylate synthase	gi|18150851	MPVAGSELPR	10.78
BTB/POZ domain-containing protein 1 isoform 2	gi|59814146	IRSLNMR	31.03
histone H2A.Z	gi|4504255	AGLQFPVGR	43.13
histone H2B	gi|1568557	LLLPGELAK	27.53
histone H4	gi|4504301	ISGLIYEETR	47.64
histone RNA hairpin-binding protein	gi|5729862	SRCSDWASAVEEDEMR	11.11
N6-adenosine-methyltransferase 70 kDa subunit	gi|21361827	EPAKK	0.47
ARP1 actin-related protein 1 homolog B	gi|119622328	RRCSTRCQTAAR	7.98

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
histone RNA hairpin-binding protein	gi|5729862	SRCSDWASAVEEDEMR	11.11
N6-adenosine-methyltransferase 70 kDa subunit	gi|21361827	EPAKK	0.47
ARP1 actin-related protein 1 homolog B	gi|119622328	RRCSTRCQTAAR	7.98
BCL-6 corepressor isoform b	gi|183396785	KMAPTVLVHSR	10.49
DNMT1 protein	gi|62204780	LAGVTLGQR	15.29
lysine-specific demethylase 4A	gi|109157941	MTLISPLMLK	27.02
myocardin isoform 2	gi|23957692	EPNEQMVR	17.16
orphan nuclear receptor	gi|1163077	VPSASQVQAIK	4.95
probable ATP-dependent RNA helicase DDX5	gi|4758138	APILIATDVASR	33.49
protein Jumonji isoform 2	gi|388490158	LNDEMR	13.55
ribosomal protein L4	gi|40889023	KPVVGKK	12.35
ribosome-binding protein 1	gi|110611218	QQLSEMK	11.4
heterogeneous nuclear ribonucleoprotein A2/B1, isoform CRA_d	gi|119614244	GGGGNFGPGPGSNFR	8.83
nuclear receptor co-repressor 2, isoform CRA_c	gi|119618857	EPTPR	1.02
putative zinc finger protein H140, partial	gi|4098632	ENSKDNSXLTK	14.75
serine/arginine-rich splicing factor 11 isoform 1	gi|4759100	TPSSSRHR	5.98

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
splicing factor 3A subunit 1 isoform 2	gi|53831995	IHEATGMPAGK	7.01
transcription factor; zinc-finger DNA-binding protein	gi|1587214	ERSGGPVTR	12.16
transcriptional coactivator p75	gi|4050036	KKGQEGKQPK	17.45
zinc finger protein 276, isoform CRA_b	gi|119587092	VNASPAGRR	8.12
tuftelin-interacting protein 11	gi|8393259	KDPSGSKK	10.87
40S ribosomal protein S14	gi|5032051	TPGPGAQSALR	16.9
40S ribosomal protein SA	gi|9845502	FAAATGATPIAGR	39.08
double stranded RNA activated protein kinase	gi|6467479	DGIISDIXDKK	5.3
EEF2 protein, partial	gi|33869643	VFSGLVSTGLK	52.26
elongation factor	gi|4503471	IGGIGTVPVGR	62.05
Transport			
alpha1A-voltage-dependent calcium channel	gi|9711929	GPGSRK	2.23
ATPase Na+/K+ transporting alpha 4	gi|33324437	LTLEELSTK	18.53
Golgin subfamily A member 6-like protein 2	gi|182662391	ATDTK	5.18
importin subunit beta-1	gi|19923142	NSAKDCYPAVQK	2.74
mitochondrial ATP synthase, H+ transporting F1 complex beta subunit	gi|89574029	IGLFGGAGVGK	29.16

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Transport			
NOP14 protein	gi|19684184	GGPAK	1.41
sorcin isoform B	gi|38679884	LSPQAVNSIAK	2.92
voltage-gated potassium channel	gi|186798	REAETLRER	13.18
ras-related protein Rab-23	gi|34485714	NEEAEALAK	6.87
Tumor suppressor			
ADAMTS18 protein	gi|19171150	KIQCVQKKPFQK	16.87
breast cancer-associated antigen BRCA1	gi|20800447	ATVVNNTK	20.58
mitochondrial tumor suppressor 1, isoform CRA_c	gi|119584210	KAEILINK	10.27
Unknown function			
ANKHZN	gi|6759376	RGSGAAEQVDNK	8.33
C5orf47 protein	gi|6716764	DAAKK	2.02
Chain A, Solution Structure Of Rsgi Ruh-022, A Myb Dna-Binding Domain In Human Cdna	gi|159163338	GSSGSSGDKEWNEK	4.61
Chain B, Crystal Structure Of The Beta-CateninICAT COMPLEX	gi|24987641	MNREGAPAK	10.89
Chain B, Pwwp Domain Of Human Bromodomain And Phd Finger-Containing Protein 1 In Complex With Trimethylated H3k36 Peptide	gi|297343131	PATGGVXKPHRY	8.58

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Unknown function			
Chromosome 1 open reading frame 105	gi|23468238	QRSSLPR	27.86
FLJ46481 protein	gi|223461603	KQHEAKLAVTPLK	18.82
hCG16178, isoform CRA_a	gi|119600436	EAGCPAGRLYR	8.94
hCG1748746	gi|119592021	NRWESAGAR	8.19
hCG1785581, isoform CRA_b	gi|119602089	VAALGR	3.02
hCG1821234	gi|119612665	GLALGTASGTGLGP	10.92
hCG1990378, isoform CRA_c	gi|119588266	INCSGK	18.23
hCG19906, isoform CRA_a	gi|119610045	CVQASTAPGGR	16.1
hCG2000808	gi|119624486	LGPAIPPK	20.95
hCG2011944	gi|119629431	MEMEPAGTKCEK	13.14
hCG2021576	gi|119608597	KTEEYGTR	12.71
hCG2038600	gi|119602014	QVSGAAQGRPTGQVHK	14.18
hCG2039044	gi|119604361	QGLTLSPR	36.77
hCG2040112	gi|119620669	MSAGALGAGRGR	2.58
hCG2040199	gi|119625937	QPPLLLPK	25.36

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Unknown function			
hCG2040385	gi|119577445	NMHSPL	14.77
hCG2040772	gi|119605533	CELGNSSL	7.5
hCG2041280, isoform CRA_a	gi|119603553	RAPSAAGGAGGCR	12.96
hCG2041407	gi|119585548	ATSSSKTLAAK	6.5
hCG2041770	gi|119620833	KMSTSNTLK	4.32
hCG2042040	gi|119588660	VDRGCEK	14.38
hCG2042887, isoform CRA_c	gi|119584883	STAPGHTSQLK	3.73
hCG2045077	gi|119577941	GAGLSSIPR	21.89
hCG2045247	gi|119588481	MSLACDRQR	5.7
hCG2045268	gi|119590405	VSPGA	12.32
hypothetical protein	gi|57161863	VPSLNGK	14.54
hypothetical protein BC006130	gi|119602791	KAAEAARMGRR	10.25
hypothetical protein FLJ37440, isoform CRA_b	gi|119572486	AAPPATASAR	10.58
kelch-like protein 35	gi|259013520	AALSAGSAYFR	8.81
KIAA1123 protein	gi|20521770	QLVVLMK	10.85

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Unknown function			
KIAA1692 protein	gi|12697929	RDRSLPR	38.5
LOC100135777 protein	gi|19263727	MGTLGQCSEK	4.9
LRRC37A2 protein	gi|219521268	INISLSIF	20.81
paraneoplastic antigen-like protein 6C	gi|283806576	ASADR	3.54
PRO2277	gi|11493445	NLENMR	23.83
protein FAM115A isoform	gi|7662276	GPNVK	12.91
protein FAM133A	gi|27734775	KKSGSSHKSR	6.82
putative	gi|553734	GITLSVRP	32.71
similar to Piccolo protein (Aczonin)	gi|51094943	VDAKVEIIK	19.3
uncharacterized protein	gi|197333715	QASDSGTGDQV	11.59
unknown	gi|37704379	NGLQTASSGAK	9.28
unknown	gi|14336678	DGTFR	1.69
unnamed protein product	gi|22761077	MVSDSLR	12.11
unnamed protein	gi|21755985	AADIIDGLRK	12.55
unnamed protein product	gi|194377686	KAKTGAAGKFK	11.1

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Unknown function			
unnamed protein product	gi|47076901	IVDRYRVGKQIGK	5.12
unnamed protein product	gi|7022134	NLIEVMRK	22.12
unnamed protein product	gi|34536392	RASVASPGEK	13.81
unnamed protein product	gi|194387024	WGHGGGRLFPR	14.38
unnamed protein product	gi|32488	DQVANSAFVER	32.68
unnamed protein product	gi|158261127	LGTMPLLPIR	13.17
unnamed protein product	gi|21757631	VQEGGFR	23.8
unnamed protein product	gi|221043958	ILMCQK	27.89
unnamed protein product	gi|194378218	DASQVSAPGTRR	8.81
unnamed protein product	gi|32486	TLTIVDTGIGMTK	23.56
unnamed protein product	gi|16553461	IGGKEVFR	25.26
unnamed protein product	gi|34531434	LLLETGMK	22.66
unnamed protein product	gi|21758470	RSLNLFR	24.53
unnamed protein product	gi|34535739	KSLALSPR	25.31
unnamed protein product	gi|34535739	KSLALSPR	28.22

Table 15 (Continued)

Protein name	Accession number	Peptide	Mowse Score
Unknown function			
unnamed protein product	gi|194391204	SAPPSLPR	25.11
unnamed protein product	gi|10432847	ALAKLTR	8.8
unnamed protein product	gi|28590	KVPEVSTPTLVEVSR	40.6
unnamed protein product	gi|28590	KVPEVSTPTLVEVSR	40.6
UPF0705 protein C11orf49 isoform 2	gi|51558748	LLLPFFR	24.92
uterus-ovary specific putative transmembrane protein UO	gi|10799170	DISSYK	17.58
WD repeat domain 46, isoform CRA_c	gi|119624108	IGSSVLRDQK	26.93

The differentially expressed proteins in various conditions have been summarized based on their biological functions including apoptosis, cell signaling, transport, structural, gene regulation, protein folding, redox-regulation, cell adhesion, cell cycle and differentiation, biomolecules biosynthesis, fibrinolysis, tumor marker, stress response, calcium binding protein, oesteogenesis, transmembrane protein, tumor suppressor, receptor, metabolism, hormone, immune system, protein-protein interaction, cell-cell interaction, proteolysis, and unknown function (Table 1). These functions were different and vary among conditions. Only the protein expressions in MS, MN, DN, and DS were further criticized in this study.

In DS, the protein functions were classified as follows: apoptosis (15%), cell signaling (15%), structural proteins (31%), protein folding (8%), transport (8%), and unknown (23%) (Figure 3A). The protein names are listed in Table 1, such as mitogaligin in apoptosis, IBtK protein and SH2 domain-containing protein in cell signaling, cytokeratin and keratin in structural proteins etc. In DN, the proteins were clustered in cell signaling (17%), structural proteins (25%), transport (8%), cell adhesion (8%), and unknown (34%) (Figure 3B). The protein names are shown in Table 2. For example, METRNL protein in cell differentiation, platelet derived growth factor receptor alpha (PDGFRA) and rho guanine nucleotide exchange factor in cell signaling, keratin, peroxisome assembly protein, and hHa protein in structural proteins etc. In MS, the protein functions were grouped as follws: apoptosis (17%), cell division (8%), transport (8%), structural proteins (8%), gene regulation (34%), and unknown (25%) (Figure 3C). The protein names are shown in Table 3, for instance, apoptosis-stimulating of p53 protein 2 (ASPP2) and apoptosis inducing factor 1 (AIF-1) in apoptosis, centrosomal protein of 63 kDa, keratin 19 in structural proteins etc. Moreover, in MN, the protein functions were divided in cell signaling (18%), structural protein (18%), fatty acid biosynthesis (9%), transport (9%), redox-regulation (9%) and unknown (37%) (Figure 3D). The proteins name are shown in Table 4, such as phospholipase C and metabotropic glutamate receptor 5 in cell signaling, tubulin-alpha and keratin in structural proteins etc.

WT1 plays a major role in the transcriptional regulatory function. The WT1 protein seems to perform two main functions, oncogene and anti-apoptosis. It regulates the transcription of a variety of target genes and is involved in post-transcriptional processing of RNA. As shown in this study, MCF-7 and MDA-MB-468 that were transfected with $siRNA_{neg}$ and $siRNA_{WT1}$ could alter hundreds of proteins. Therefore, the proteins implicated in apoptosis and cell signaling were emphasized in detail. Cathepsin D, apoptosis inducing factor, and

apoptosis stimulating of p53 protein were up-regulated only when WT1 was silenced in MCF-7. Moreover, the proteins associated with the signal transduction pathway: 14-3-3 epsilon, signal transducing adaptor protein 1, phospholipase C, and metabotropic glutamate 5 receptor (GRM5) were found only in $siRNA_{neg}$ (WT1 present) (Table 16). These selected proteins are described below.

Table 16 Unique Protein expression in $siRNA_{neg}$ and $siRNA_{WT1}$ in MCF-7

MCF-7 $siRNA_{neg}$		MCF-7 $siRNA_{WT1}$	
2-DE	**1-DE**	**2-DE**	**1-DE**
Cell signaling:		**Apoptosis:**	
14-3-3 epsilon	Phospholipase C	Cathepsin D	Apoptosis inducing factor
Signal transducing adaptor protein 1	Metabotropic 5 glutamate receptor		Apoptosis stimulating of p53 protein

Cathepsin D is an intracellular aspartic protease present in the endosomes and lysosomes of all mammalian cells. Cathepsin D is also a key mediator of apoptosis induced by many apoptotic agents such as IFN-γ, Fas/APO, and TNF-α (Deiss *et al*., 1996). The role of cathepsin D in apoptosis showed in Figure 4. After the induction of apoptosis, selective permeabilization of lysosomal membrane results in the release of mature cathepsin D into cytosol. The release of cathepsin D may cleave Bid, following formation of active Bax conformation and insertion in the outer mitochondrial membrane, or may interact with unknown partners (Beaujouin *et al*., 2006) leading to release of the cytochrome c from the mitochondria. The release of cytochrome c activates caspase-9 and caspase-3 (Heinrich *et al*., 2004) resulting in apoptosis. Alternatively, presence of cathepsin D in cytosol may trigger Bax activation via Bid-independent pathway, resulting in release of apoptosis inducing-factor (AIF) resulting to apoptosis (Bidere *et al*., 2003). Many studies reported that cathepsin D synthesis is regulated by estrogen in estrogen receptor positive breast cancer (Duffy *et al*., 1991). Cathepsin D can act as a prognostic marker in breast cancer (Tandon *et al*., 1990).

Furthermore Liaudet *et al*, (2006) showed that cathepsin D over-expressed and acted as a poor prognosis marker in breast cancer.



Figure 4 The role of cathepsin D in apoptosis (Adapted from: Benes, vetvicka and Fusek, 2008)

Apoptosis-inducing factor 1 (AIF-1) mitochondrion is a protein triggering chromatin condensation and DNA degradation in a cell in order to induce a caspase-independent pathway of apoptosis (Joza *et al*., 2001). It normally presents in the mitochondrial inter-membrane space and is released in response to death stimuli (Susin *et al*., 1999). The process of stimulating apoptosis starts when the mitochondrion releases AIF-1, which exits through the mitochondrial membrane, enters the cytosol, and finally ends up in the cell nucleus where it signals the cell to condense its chromosomes and fragment its DNA molecules in order to prepare for cell death (Hangen *et al*., 2010).

Apoptosis stimulating factor of p53 protein 2 (ASPP2), also referred to as 53BP2L, enhances p53-induced apoptosis (Samuels *et al*., 2001) and is downstream of E2F suggesting that it functions as a common link between the p53/p73 and Rb/E2F apoptotic pathways (Chen *et al*., 2005).

14-3-3 epsilon, a protein of the 14-3-3 family mediates signal transduction by binding to phosphoserine-containing proteins. It interacts with cell division cycle 25 phosphatases (CDC25A, CDC25B and CDC25C) (Forrest and Gabrielli, 2001). Different CDC25s participate in different phases of cell cycle. CDC25A takes part in regulation of G1/S transition, whereas CDC25B and CDC25C regulate G2/M transition via CDK1 (Sancar *et al*., 2004) (Figure 5). Furthermore, Zuo *et al*, (2009) reported that TNF-α stimulation enhances the interaction between 14-3-3 epsilon and some key components in MAPK pathway locating at the upstream of NF-kB, including transforming growth factor-beta activated kinase-1 (TAK1) and its interacting protein and protein phosphatase 2Cβ. These studies revealed that 14-3-3 epsilon coordinates the crosstalked between the MAPK signal module and other molecular pathways or biological processes including protein metabolism and synthesis, DNA repair, and cell cycle regulation.

Signal transducing adaptor protein 1 is a protein involved in a signal transduction pathway. Signal transducing adaptor protein 1 contains a variety of protein-binding modules that link protein-binding partners together and facilitate the creation of larger signaling complexes. It contains Src homology 2 (SH2) and SH3 domains which allow specific interactions with several other specific proteins. SH2 domains recognize specific amino acid sequences within proteins containing phosphotyrosine residues and SH3 domains recognize proline-rich sequences within specific peptide sequence contexts of proteins (National Library of Medicine-Medical Subject Headings, 2011).

Phospholipase C (PLC) plays a key role in the signal transduction process for many receptors. PLC cleaves a phospholipid phosphatidylinositol 4,5-bisphosphate (PIP_2) into diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG remains bound to the membrane, and IP_3 is released into the cytosol. IP_3 then diffuses through the cytosol to bind to IP_3 receptors, particular calcium channels in the smooth endoplasmic reticulum (ER). This causes calcium level increasing in cytosol, causing a cascade of intracellular changes and activity. In addition, calcium and DAG together work to activate protein kinase C, which goes on to phosphorylate other molecules, leading to alter cellular activity (Figure 6) (Alberts *et al*., 2008).



Figure 5 Role of 14-3-3 epsilon in cell cycle regulation

Adapted from: http://pathwaymaps.com/maps/647/#647_11466620



Figure 6 Role of Phospholipase C and other molecules in signal transduction pathway (Alberts *et al.*, 2008)

Metabotropic glutamate 5 receptor (GRM5); The metabotropic glutamate receptors belong to a family of G protein-coupled receptors, that have been divided into 3 groups. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade (Nicoletti *et al.*, 2011).

Additionally, in MDA-MB-468, the proteins involving apoptosis, including ALG-2 interacting protein x, apoptosis- inducing factor 1 were found when WT1 was present ($siRNA_{neg}$) while mitogaligin was detected in the $siRNA_{WT1}$ condition. Furthermore, the proteins related in the signaling pathway found in $siRNA_{neg}$ included guanine nucleotide binding protein, neuropolypeptide h3, PDGFRA and Rho guanine nucleotide exchange factor 1 while IBTK protein, and SH2 domain containing protein were expressed in $siRNA_{WT1}$ (Table 17).

Table 17 Unique Protein expression in $siRNA_{neg}$ and $siRNA_{WT1}$ in MDA-MB-468

MDA-MB-468 $siRNA_{neg}$		MDA-MB-468g $siRNA_{WT1}$	
2-DE	**1-DE**	**2-DE**	**1-DE**
Cell signaling:		**Cell signaling**:	
Guanine nucleotide binding protein	PDGFRA	-	IBtK protein
Neuropolypeptide h3	Rho guanine nucleotide exchange factor 1	-	SH2 domain containing protein
Apoptosis:		-	
ALG-2 interacting protein x	-	-	Mitogaligin
Apoptosis-inducing factor 1	-	-	-

ALG-2-interacting protein X (Alix) or Hp95, also known as AIP1 was reported to interact with the calcium-binding protein ALG-2 (apoptosis-linked gene 2), which was necessary for cell death (Missotten *et al*., 1999).

Mitogaligin, a cell death protein, contains a mitochondrial targeting sequence and promotes the release of cytochrome c into the cytosol. Additionally, mitogaligin localizes in nucleus and induces cell death through a pathway exhibiting typical properties

of apoptosis causing cell shrinkage, cytoplasm vacuolization, nuclei condensation, and eventually cell death (Robinet *et al*., 2010).

Platelet derived growth factor receptor alpha (PDGFRA) is a cell surface tyrosine kinase receptor important factors which is an important regulating cell proliferation, cellular differentiation, cell growth, and development (Heldin *et al*., 1989). After ligand binding, the platelet-derived growth factor receptor (PDGFR), dimerize via autophosphorylation (P) and recruit adaptor proteins (such as GRB2 and SHC) that activate various downstream effectors via MAPK or PI3K pathway resulting in cell proliferation (Alberts *et al*., 2008).

Rho guanine nucleotide exchange factor is an intracellular signaling molecule that regulates cytoskeleton organization, gene expression, cell cycle progression, cell motility, and other cellular processes. It represents the activating enzymes of Rho GTPases by serving to relay a variety of signals to catalyze GDP/GTP exchange of specific Rho GTPases (Shang *et al*., 2013). Rho-GEF is related in Rho GTPases activity which controlled by three types of proteins: Rho-guanine nucleotide exchange factors (Rho-GEF), which catalyses the exchange of GDP for GTP, resulting the protein active, GTPase activating proteins (GAPs), which stimulate the intrinsic GTPase activity, turning off the GTPase, and guanine nucleotide dissociation inhibitors (GDIs), whose role appears to block spontaneous activation (Figure 7)

Inhibitor of Bruton's tyrosine kinase (IBtK) is a negative regulator of the Bruton tyrosine kinase (BtK), which play a major role in B-cell differentiation and down-regulated BtK kinase activity (Liu *et al*., 2001). However Janda *et al*, (2011) reported that IBtK is phosphorelated with at serine 87 and 90 by PKC. This phosphorylation causes the dissociation of the interaction between BtK and IBtK and allows BtK to translocate to the plasma membrane.



Figure 7 The role of Rho-GEF in Rho-GTPase activity of signaling pathway (Garcia *et al*., 2006)

SH2 domain containing prorein is a sequence specific phosphotyrosine-binding module present in many signaling molecules including tyrosine kinase. In cytoplasmic tyrosine kinases, the SH2 domain is located N-terminally to the catalytic kinase domain (SH1) where it mediates cellular localization, substrate recruitment, and regulation of kinase activity (Filippakopoulos, Mu ller and Knapp, 2009).

Guanine nucleotide binding protein or G-protein is important for relaying signal from G-protein linked receptor to intracellular enzymes or ion channel (Alberts *et al*., 2008). G-protein activates phospholipase C which cleaves a phospholipid phosphatidylinositol 4,5-bisphosphate (PIP_2) into diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) leading to altered cellular activity or it may activate adenylyl cyclase relating in signal transduction pathway via cyclic AMP- dependent pathway (Figure 6) (Alberts *et al*., 2008).

Neuropolypeptide h3, also known as Raf kinase inhibitor protein as been shown to inhibit Raf and thereby negatively regulate growth factor signaling by the Raf/MAP kinase pathway. RKIP has also been shown to suppress metastasis (Shemon *et al*., 2010)

Protein identification from 1-DE and 2-DE combined with LC-MS/MS was classified into various groups according to biological function, such as cell signaling, apoptosis, structural proteins, protein folding, metabolism, unknown etc. However, the proteins involved in apoptosis and cell signaling were only discussed in each cell line in this study.

1. WT1 and apoptosis pathway in MCF-7

The evidence of the relationship between WT1 and other proteins in the apoptosis pathway was explored using STRING 9.05 database. Figure 8A shows the association of WT1 and other proteins relevant to the apoptosis pathway. The action modes of these proteins have been shown in different colors, such as green, red, blue, and light blue. They refer to activation, inhibition, binding, and phenotypes, respectively. Grey lines refer to the relationship of proteins but the mode of actions has not been reported (Figure 8B). The result revealed the binding of WT1 and p53 which was agreeable from previous studies that WT1 closely interacts with the p53, tumor suppressor gene. Interaction between p53 and WT1 leads to stabilize the expression of p53 resulting in p53 over-expression and long half-life. WT1 appears to inhibit the apoptotic effect of p53 but not its ability to induce cell cycle arrest (Maheswaran *et al*., 1995). However, the direct association between WT1 and the other proteins related in the apoptosis pathway has not been found the STRING 9.05

database. In this study, cathepsin D, AIF-1, and ASPP2 were indirectly related to WT1 via p53 protein (Figure 8).

MCF-7 contains estrogen and progesterone receptor, no HER2 expression, p53 wild type, and expresses IGFBP. Under $siRNA_{WT1}$ transfection, proteins involved in the apoptosis pathway were up-regulated. This communication was elicited through p53. Without WT1 in the cell, p53 was released and allowed to trigger an intracellular signal transduction cascade leading to gene activation of cathepsin D and ASPP2. Alternatively, presence of cathepsin D triggers Bax activation via the Bid-independent pathway, resulting in release of AIF-1 leading to apoptosis. Previous studies reported that cathepsin D synthesis was regulated by estrogen in estrogen positive breast cancer (Duffy *et al*., 1991). In this study, the possible relationship between WT1 and related molecules has been proposed in Figure 9.



Figure 8 (A) The involvement of WT1 and proteins in apoptosis pathway in MCF-7 (STRING 9.05). (B) Modes of action are shown in different colors. The red circle shows the proteins found in this study.



Figure 9 The possible relationship between WT1 and cathepsin D, AIF-1, and ASPP2 in MCF-7 when knockdown WT1 with siRNA$_{WT1}$. (Adapted from: Benes, vetvicka and Fusek, 2008)

2. WT1 and signaling pathway in MCF-7

When WT1 is present, 14-3-3 epsilon, signal transducing adaptor protein 1, phospholipase C, and metabotropic glutamate receptor 5 protein were up-regulated. The STRING 9.05 showed that WT1 interacted with many genes involved in cell survival and cell growth, such as IGFR-1, EGFR, C-Myc, Syndecan-1, etc. (Figure 10). However, the direct association between WT1 and 14-3-3 epsilon, signal transducing adaptor protein 1 (STAP1), phospholipase C (PLC), and metabotropic glutamate receptor 5 protein (GRM5) has never been reported according to STRING 9.05 database.

The possible correlation between WT1 and 14-3-3 epsilon, STAP1, PLC, and GRM5 is shown in Figure 11. WT1 may crosstalk with STAP1, PLC, and GRM5. PLC cleaves a PIP_2 to IP_3 and DAG. IP_3 activates the release of Ca^{2+} into cytosol to bind with calmodulin. The binding of Ca^{2+}/calmodulin triggers Ca^{2+}/calmodulin-dependent kinase (CAM-kinase) to phosphorylate many targeted proteins involved in cell growth. In addition, Ca^{2+} and DAG together activated protein kinase C (PKC) leading to phosphorylate other molecules, resulting in cell proliferation. Moreover, WT1 may crosstalk with 14-3-3 epsilon to trigger

cyclin-dependent kinases (CDKs) or activate the MAPK pathway. These relationships may occur at transcription or translation level resulting to cell proliferation or cell growth.

Consequently, WT1 plays an oncogenic role in MCF-7. When WT1 is present, the proliferative signaling pathway has been amplified through 14-3-3 epsilon, PLC, and GRM5. Unlike in the siRNA$_{WT1}$ condition, WT1 behaves as an anti-apoptotic molecule by activating cathepsin D and ASPP2 through p53.



SDC1 = Syndecan-1

INSR = Insulin receptor

IGFBP4 = Insulin like growth factor binding protein 4

IGF1R = Insulin like growth factor-1 receptor

IGF-2 = Insulin like growth factor-2

PDGFA = Platelet derived growth factor alpha

U2AF2 = U2 auxiliary factor 2

AREG = Amphiregulin

EGFR = Epidermal growth factor receptor

ESR1 = Estrogen receptor

AR = Androgen receptor

CDC25A = Cell division cycle 25 A

CDK1, CDK2, CDK5 = Cyclin-dependent kinase 1, 2, 5

ADAMTS1 = A disintegrin and metalloproteinase with thrombospondin motifs 1

MYC, MYB = C-Myc, C-Myb

CDKN1C = Cyclin-dependent kinase inhibitor 1

Figure 10 (A) The involvement of WT1 and proteins in signal transduction pathway in MCF-7 (STRING 9.05). (B) Modes of action are shown in different colors. The red circle shows the proteins found in this study.



Figure 11 The possible relationship between WT1 and phospholipase C, GRM5, Signal transducing adapter protein1, and 14-3-3 epsilon in signal transduction pathway. Adapted from: Alberts *et al*., 2008

3. WT1 and apoptosis in MDA-MB-468

Due to p53 mutation in MDA-MB-468, the apoptosis pathway may occur via p53 independently. Surprisingly, a novel target protein of WT1, mitogaligin, was found in MDA-MB-468 when WT1 was silenced. The STRING shows no correlation between WT1 and mitogaligin from previous studies (Figure 12).

Mitogaligin contains a mitochondrial targeting sequence and promotes the release of cytochrome C. It induces cell death through the apoptosis pathway (Robinet *et al.,* 2010). The relationship between WT1 and motogaligin assumed that WT1 may act as negative regulator of mitogaligin at transcription or translation level. However, the relationship between WT1 and ALG-2 interacting protein x, apoptosis- inducing factor 1 has not been

elucidated. There was not enough evidence to clarify the correlation of WT1 and selected molecules. Therfore, further works will be required to investigate this hypothesis.



Figure 12 (A) The involvement of WT1 and p53-independent apoptosis pathway in MDA-MB-468 (STRING 9.05). (B) Modes of action are shown in different colors. The red circle shows the proteins found in this study.

4. WT1 and signaling pathway in MDA-MB-468

The signal transduction pathway in MDA-MB-468 breast cancer cell line was related with the mTOR signaling pathway that regulates cell growth, proliferation, differentiation, and survival (Yu *et al*., 2001). mTOR protein exists in two distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 contains the protein *raptor* while mTORC2 contains the protein *rictor*. In the presence of growth factors, activated Akt phosphorylates and inhibits tuberous sclerosis protein 2 (Tsc2), thereby promoting the activation of Rheb. Activated Rheb (Rheb-GTP) helps activate mTORC1, which in turn stimulates cell growth. Forthermore, mTORC2 phosphorylates Akt at Ser473 and regulates the actin cytoskeleton and cell motility (Zhou *et al*., 2010) (Figure 13). Recently, Razmara *et al*, (2013) demonstrated that PDGFRs are essential for multiple growth factor signaling

pathways that lead to PI3K/Akt activation. The pathway from PDGFR leads to phosphorylation of Akt which involves both the mTORC2 and PLCγ/PKC pathways.



Figure 13 Activation of mTOR by the PI-3-kinase-Akt signaling pathway
Adapted from: Zhou and Huang, 2010; Albert *et al.,* 2008

WT1 interacted with many genes involved in the cell signaling pathway (Figure 14). In this study, the proteins involved in the cell signaling pathway, PDGFRA and rho-GEF were found when WT1 was present in MDA-MB-468, while G-protein, SH2 domain containing protein, and neuropolypeptide h3 were found when the cell was without WT1. However, the STRING 9.05 showed that these molecules were not associated.



PDGFRA = Platelet derived growth factor receptor alpha

RARA = Retinoic acid receptor alpha

IBtK = Inhibitor of Bruton's tyrosine kinase

Figure 14 (A) The involvement of WT1 and proteins in signal transduction pathway in MDA-MB-468 (STRING 9.05). (B) Modes of action are shown in different colors. The red circle shows the proteins found in this study.



Figure 15 The possible relationship between WT1 and PDGFRA, Rho-GEF in signal transduction pathway in MDA-MB-468 (Adapted from: Zhou and Huang 2010)

In this study, WT1 may relate with PDGFRA leading to activation of Akt/ TSC1, TSC2/mTOR2 pathway resulting in cell growth. Moreover, WT1 may also associate with mTOR2/Rho-GEF resulting in cell motility (Figure 15). Thus, WT1 plays an oncogenic role in MDA-MB-468. Moreover, when WT1 was silenced with $siRNA_{WT1}$, IBtK, SH2 domain containing protein, G-protein, and neuropolypeptide h3 were up-regulated. The relationship between WT1 and these proteins in signaling pathway in MDA-MB-468 has not prior been elucidated. WT1 may behave as a negative regulator of IBtK that bind to SH2 domain of BtK tyrosine kinase receptor resulting in IBtK inactivate leading to B-cell differentiation. Furthermore, WT1 possibly be a negative regulator of Raf kinase inhibitor resulting to activation MAPK pathway and promote metastasis. The overview of the relationship between WT1 and proteins in MCF- and MDA-MB-468 were shown in Figure 14-15. The red alphabet refers to the proteins found in this study.

References

Adami HO, Signorello LB, Trichopoulos D. Towards an understanding of breast cancer etiology. Cancer Biol 1998; 8: 255-62.

Albert B, Johnson A, Walter P, Lewis J, Raff M, Robert K. Molecular biology of the cell. 5th ed. New York: Garland Science; 2008.

Beaujouin M, Baghdiguian S, Glondu LM, Berchem G, Liaudet CE. Overexpression of both catalytically-active and -inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity. Oncogene 2006; 25: 1967-73.

Benes P, Vetvicka V, Fusek M. Cathepsin D-many functions of one aspartic protease. Crit Rev Oncol Hematol 2008; 68; 12-28.

Burwell EA, McCarty GP, Simpson LA, Thompson KA, Loeb DM. Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Oncogene 2007; 26: 3423-30.

Call K, Glaser T, Ito C, Buckler A, Pelletier J, Haber D, et al. Isolation and characterization of zinc finger polypeptide gene at chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-20.

Chen D, Padiernos E, Ding F, Lossos IS, Lopez CD. Apoptosis-stimulating protein of p53-2 (ASSP2/53BP2L) is an E2F target gene. Nature 2005; 12: 358-68.

Chen S, Pan T, Tsai Y, Huang C. Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett 2002; 181: 95-107.

Delehedde M, Boilly B, Hondermarck H. Differential responsiveness of human breast cancer cells to basic fibroblast growth factor: a cell kinetics study. Oncol Res 1995; 7: 399-405.

Davies JA, Ladomery M, Hohenstein P, Michael L, Shafe A, Spraggon L, et al. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the WT1 tumour suppressor is required for nephron differentiation. Hum Mol Genet 2004; 13: 235-46.

Deiss LP, Galinka H, Berissi H, Cohen O, Kimchi A. Cathepsin D protease mediates programmed cell death induced by interferon gamma, Fas/APO-1 and TNF alpha. EMBO J 1996; 15: 3861–70.

Dorsett Y, Tuschl T. siRNAs: Applications in functional genomics and potential as therapeutics. Nature 2004; 3: 318-29.

Duffy MJ, Broullet JP, Rellly D, McDermott E, O'Higgins N, Fennelly JJ. Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings. Clin Chem 1991; 37: 101-4.

Dumitrescu R, Cotarla I. Understanding breast cancer risk where do we stand in 2005? J Cell Mol Med 2005; 9: 208-21.

Duneau M, Boyer GM, Gonzalez P, Charpentier S, Normand T, Dubois M, et al. A novel cell death gene that encodes a mitochondrial protein promoting cytochrome c release. Exp Cell Res 2005; 302: 194-205.

Elmaagacli AH, Koldehoff M, Peceny R, Klein LH, Ottinger H, Beelen DW, et al. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 2005; 90: 326-34.

Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.

Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber DA. Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res 1997; 57: 1429-34.

Filippakopoulos P, Muller S, Knapp S. SH2 domains: modulators of nonreceptor tyrosine kinase activity. J Struct Biol 2009; 19: 643-9.

Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans.* Nature 1998; 391: 806-11.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBO CAN 2008. Int J Cancer 2010; 127: 2893-917.

Forrest A, Gabrielli B. Cdc25B activity is regulated by 14-3-3. Oncogene 2001; 20: 4393-401.

Garcıa P, Tajadura V, Garcıa I, Sanchez Y. Role of Rho GTPases and Rho-GEFs in the regulation of cell shape and integrity in fission yeast. Yeast 2006; 23: 1031-43.

Geiger T, Madden SF, Gallagher WF, Cox J, Mann M. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res 2012; 72: 2428-39.

Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 34: 774-8.

Gonzalez P, Robinet P, Charpentier S, Mollet L, Normand T, Dubois M, et al. Apoptotic activity of a nuclear form of mitogaligin, a cell death protein. BBRC 2009; 378: 816-20.

Graidist P. The role of WT1 in breast and other cancers: oncogene or tumor suppressor gene? Songkla Med J 2009; 27: 435-49.

Graidist P, Nawakhanitworakul R, Saekoo J, Dechsukhum C, Fujise K. Anti-apoptotic function of T-KTS+, T-KTS-, WT1+/+ and WT1+/- isoforms in breast cancer. Asian Biomed 2010; 4: 711-20.

Haber DA, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, et al. WT1-mediated growth suppression of Wilms tumor cells expression a WT1 splicing variant. Science 1993; 226: 2057-9.

Han Y, San SM, Liu J, Midden MD. Transcriptional activation of c-myc proto-oncogene by WT1 protein. Oncogene 2004; 23: 6933-41.

Hangen E, Blomgren K, Paule B, Kroemer G, Modjtahedi N. Life with or without AIF. Cell 2010; 35: 278-86.

Hames BD, Rickwood D. Gel electrophoresis of proteins: a practical Approach. 2nd ed. New York: Oxford University Press; 1990.

Hewitt SM, Hamada S, McDonnell TJ, Raucher FJ, Saunders G. Regulation of the proto-oncogenes bcl-2 and c-myc by the wilms' tumor suppressor gene WT1. Cancer Res 1995; 55: 5386-9.

Hondermarck H, Vercoutter AS, Révillion F, Lemoine J, Yazidi IB, Nurcombe V, et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 2001; 10: 1216-32.

Holiday LD, Speirs V. Choosing the right cell line for breast cancer research. Breast Can Res 2011; 13: 1-7.

Heldin CH, Westermark B. Platelet-derived growth factor: three isoforms and two receptor types. Trends Genet 1989; 5: 108–11.

Hosako M, Muto T, Nakamura Y, Tsuta K, Tochigi N, Tsuda H, et al. Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker. J Proteomics 2012; 75: 833-44.

Idelman G, Glaser T, Roberts CT, Werner H. WT1-p53 interactions in insulin-liked growth factor-I receptor gene regulation. J Biol Chem 2003; 278: 3474-82.

Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T, et al. Antiapoptotic function of 17AA(+) WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 2006; 25: 4217-29.

Jensen LJ, Kuhn M, Stark M, Chaffron M, Creevey C, Muller J, et al. STRING 8—a global view on proteins and their functional interactions in 630 organisms. Nucl Acids Res 2009; 37: D412-16.

Janda E, Palmieri C, Pisano A, Pontoriero M, Laccino E, Falcone C. Btk regulation in human and mouse B cells via protein kinase C phosphorylation of IBtk. Blood 2011; 117: 6520-31.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 67-8.

Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A. Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 2006; 97: 259-70.

Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001; 410; 549-54.

Kennerdell JR, Carthew RW. Use of dsRNA-mediated genetic interference to demonstrate that *frizzled* and *frizzled2* act in the wingless pathway. Cell 1998; 95: 1017-26.

Khuhaprema T, Srivatanakul P, Attasara P, Sriplung H, Wiangnon S, Sumitsawan Y. Cancer in Thailand Volume V 2001-2003. Ministry of public health and ministry of education. Bangkok; 2010.

Koziell A, Grundy R. Frasier and Denys-Drash syndromes: different disorders or part of a spectrum?. Arch Dis Child 1999; 81: 365-9.

Liaudet CE, Beaujouin M, Derocq D, Garcia M, Glondu ML, Laurent VM, et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 2006; 237: 167–179.

Li H, Oka Y, Tsuboi A, Yamagami T, Yamagami T, Miyazaki T, et al. The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells. Int J Hematol 2003; 77: 463-70.

Liu W, Quinto I, Chen X, Palmieri C, Rabin RL, Schwartz MO. Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein. Nature 2001; 2: 939-46.

Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumor despite tumor specific promoter methylation. Cancer Res 2001; 61: 921-5.

Loeb DM. WT1 influences apoptosis through transcriptional regulation of Bcl-2 family

members. Cell Cycle 2006; 5: 1249-53.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagen. J Biol Chem 1951; 193: 265-75.

Madden SL, Cook DM, Rauscher FJI. A structure-function analysis of transcriptional repression mediated by the WT1, Wilms' tumor suppressor protein. Oncogene 1993; 8: 1713-20.

Maheswaran S, Englert C, Bennett P, Heinrich G, Haber A. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 1995; 9: 2143-56.

Mayo M, Wang C, Drouin S, Madrid L, Marshall A, Reed J, et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999; 18: 3990-4003.

McMaster ML, Gessler M, Stanbridge EJ, Weissman BE. WT1 expression alters tumorigenicity of the G401 kidney-derived cell line. Cell Growth Differ 1995; 6: 1609-17.

Menke AL, Shvarts A, Riteco N, VanHam RC, Vander AJ, Jochemsen AG. Wilms' tumor 1- KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor. Cancer Res 1997; 57: 1353-63.

Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002; 8: 1167-71.

Missotten M, Nichols A, Rieger K, Sadoul R. Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Nature 1999; 6: 124-29.

Morrison DJ, English MA, Licht JD. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak. Cancer Res 2005; 65: 8174-82.

Morrison AA, Viney RL, Saleem MA, Ladomery MR. New insights into the function of the Wilms tumor suppressor gene *WT1* in podocytes. Am J Physiol Renal Physiol 2008; 295: F12-7.

National Library of Medicine-Medical Subject Headings [Internet]. Rockville Pike, Bethesda; c2013 [updated 2013 March 1; cited 2013 March 14]. Available from: http://www.nlm.nih.gov/mesh/.

Navakanit R, Graidist P, Leeanansaksiri W, Dechsukum C. Growth inhibition of breast cancer cell line MCF-7 by siRNA silencing of Wilm tumor 1 gene. J Med Assoc Thai 2007; 90: 2416-21.

Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD. Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology 2011; 60: 1017-41.

Nielsen TO, Hsu FD, Jensen K, Cheang M , Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-74.

Oelgeschlager M, Larrain J, Geissert D, Robertis EM. The evolutionarily conserved BMP-binding protein twisted gastrulation promotes BMP-signaling. Nature 2000; 405: 757-63.

Oji Y, Miyoshi Y, Kiyotoh E, Koga S, Nakano Y, Ando A, et al. Absence of mutations in the Wilms' tumor Gene *WT1* in Primary Breast Cancer. Jpn J Clin Oncol 2004; 34: 74-7.

Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000; 405: 837–846.

Razmara M, Heldin CH, Lennartsson J. Platelet-derived growth factor-induced Akt phosphorylation requires mTOR/Rictor and phospholipase C-γ1, whereas S6 phosphorylation depends on mTOR/Raptor and phospholipase D**.** J Cell Commun Signal 2013; 11: 1-12.

Robinet O, Mollet L, Gonzalez P, Normand T, Charpentier S, Brul F. The mitogaligin protein is addressed to the nucleus via a non-classical localization signal. BBRC 2010; 392: 53-7.

Samuels YL, O'Connor D, Bergamaschi D, Trigiante G, Camparque I, Naumovski L, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 781-94.

Sancar A, Lindsey LA, Unsal KK, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73: 39-85.

Scholz H, Kirschner KM. A role for the Wilms tumor protein WT1 in organ development. Physiology 2005; 20: 54-9.

Shang X, Marchioni F, Evelyn CR, Sipes N, Zhou X, Seibel W, et al. Small-molecule inhibitors targeting G-protein–coupled Rho guanine nucleotide exchange factors. PNAS 2013; 110: 3155-60.

Shemon AN, Heil JL, Granovsky HE, Clark MM, McElheny D, Chimon A, et al. Characterization of the raf kinase inhibitory protein (RKIP) binding pocket: NMR-based screening identifies small-molecule ligands. PLOS ONE 2010; 5: 1-13.

Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004; 64: 9018-26.

Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr, Daniel CW. Altered expression of WT1 Wilms' tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997; 94: 8132-7.

Smith SI, Down M, Boyd AW, Li CL. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice. Cancer Res 2000; 60: 808-14.

Soule HD, Vasquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 1409-13.

Stein R, Zvelebil M. The Application of 2D Gel-Based Proteomics Methods to the Study of Breast Cancer. J Mammary Gland Biol Neoplasia 2002; 7: 385-93.

Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer: Basic Clin Res 2010; 4: 35–41

Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441-6.

Tandon KA, Clark GM, Chamness GC, Chirgwin JM, McGuire W. Cathepsin D and prognosis in breast cancer. NEJM 1990; 322: 297-302.

Valle A, Sastre-Serra J, Pol C, Mir ´o A, Oliver J, Roca P. Proteomic analysis of MCF-7 breast cancer cell line exposed to leptin. Anal Cell Pathol 2011; 34: 147-57.

Viney RL, Morrison AA, van den Heuvel LP, Ni L, Mathieson PW. A proteomic investigation of glomerular podocytes from a Denys-Drash Syndrome patient with a mutation in the Wilms tumour suppressor gene WT1. Proteomics 2007; 7: 804-15.

Wang Z, Qiu Q, Huang J, Gurrieri M, Deuel TF. Products of alternative splice transcripts of The Wilms' tumor suppressor gene, WT1, have altered DNA binding specificity and regulate transcription in dtfferences ways. Oncogene 1995; 10: 415-22.

Wagner KD, Wagner N, Schedl A. The complex life of WT1. J Cell Sci 2003; 116: 1653-8.

Wilkins MR, Pasquali C, Appel RD, Ou K, Golaz O, Sanchez JC, et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (NY) 1996; 14: 61-5.

Yang L, Han Y, Saurez Saiz F, Minden M. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868-76.

Yu K, Toral LB, Discafani C, Zhang WG, Skotnicki J, Frost P. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-58.

Zhou H and Huang S. mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr. 2010; 20: 1–16.

Future works

This work should be further functional studies such as immunuprecipitation, functional proteomics (affinity chromatograpy, protein-protein interaction, protein-promoter interaction etc.) should be performed to determine these hypotheses.